Connect Biopharma

Monoclonal antibodies
#Chronic obstructive pulmonary disease (COPD) #Connect Biopharma #Monoclonal antibodies #Phase II trial

Monoclonal antibody reduces COPD exacerbations in Phase II trial

Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody.  The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More

#News